Replies to post #167610 on Biotech Values

[oc631]

[ABBV] that would’ve accomplished the same thing as having two trials devoted to cirrhotic patients as you suggested.

TURQUOISE-2 already had a 12w and 24w arm within the single trial design. So I'm speculating that ABBV designed TURQUOISE-1 in a similar manner (two trials split between GT1A and GT1B).

I prefer the design you suggested.